GlassScriptPhysician profile
Sandy P Naples
NPI 1295728764
$1,551.12
in general payments reported to CMS, 2019-2025
27 companies · $27.52 in 2025
The $27.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $270 · 2021: $17.06 · 2022: $12.94 · 2023: $12.87 · 2024: $126 · 2025: $27.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $166.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $255.47 | 2019-2020 | |
| Amgen INC. | $223.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $163.15 | 2019-2024 | Tezspire |
| Abbvie INC. | $142.88 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $119.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $92.58 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.70 | 2019 | |
| Novo Nordisk INC | $55.40 | 2019-2020 | |
| Amarin Pharma, INC. | $54.82 | 2019 | |
| Allergan, INC. | $43.45 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $41.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.44 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.14 | 2020 | |
| Pulmonx Corporation | $27.52 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Sanofi-Aventis U.S. LLC | $24.61 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $22.61 | 2019 | |
| Promius Pharma LLC | $17.02 | 2019 | |
| Abbott Laboratories | $17.01 | 2019 | |
| Astellas Pharma US INC | $16.50 | 2020 | |
| Avanir Pharmaceuticals, INC. | $16.06 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.08 | 2019 | |
| Nabriva Therapeutics, Plc | $12.83 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.48 | 2019 | |
| Ibsa Pharma INC. | $11.20 | 2019 | |
| Glaxosmithkline, LLC. | $10.88 | 2019 | |
| Fidia Pharma USA INC. | $8.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Naples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.